- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.02. | SAB Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 28.01. | Why Is SAB BIO Stock Trading Lower On Tuesday? | 6 | Benzinga.com | ||
| 28.01. | Pre-market Movers: IMAC Holdings, Planet Image International, SAB Biotherapeutics, MicroCloud Hologram, Avalon Holdings | 565 | AFX News | BEIJING (dpa-AFX) - The following are some of the stocks making big moves in Tuesday's pre-market trading (as of 08.30 A.M. ET).In the Green IMAC Holdings, Inc. (BACK) is up over 91% at $1.59.
Planet... ► Artikel lesen | |
| 28.01. | SAB Biotherapeutics, Inc.: SAB BIO Announces Positive Topline Phase 1 Clinical Results with Potentially Disease-Modifying T1D Therapy SAB-142 | 365 | GlobeNewswire (Europe) | SAB-142 was generally well-tolerated among healthy volunteers; data from Phase 1 trial confirms SAB-142 does not cause serum sickness or anti-drug antibodies at target dose Study results support... ► Artikel lesen | |
| 28.01. | SAB Biotherapeutics, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 23.01. | SAB Biotherapeutics, Inc.: SAB BIO Announces R&D Webinar Event to Review Phase 1 Topline Results for SAB-142, a Disease-Modifying T1D Therapy | 4 | GlobeNewswire (USA) | ||
| SAB BIOTHERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 06.01. | Here's Why SAB Biotherapeutics, Inc. (NASDAQ:SABS) Is Among the Best Diabetes Stocks to Buy Under $10 | 1 | Insider Monkey | ||
| 07.11.24 | SAB Biotherapeutics GAAP EPS of -$1.12 | 1 | Seeking Alpha | ||
| 06.11.24 | SAB Biotherapeutics, Inc.: SAB BIO Announces Third Quarter 2024 Financial Results and Provides Company Update | 153 | GlobeNewswire (Europe) | Company announced completed Phase 1 enrollment for SAB-142 with no observation of serum sickness. The company remains on track for a topline Phase 1 data readout by the end of the year. MIAMI, Nov.... ► Artikel lesen | |
| 06.11.24 | SAB Biotherapeutics, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 08.08.24 | SAB Biotherapeutics, Inc.: SAB BIO Announces Second Quarter 2024 Financial Results and Provides Company Updates | 215 | GlobeNewswire (Europe) | FDA provided clearance to SAB's IND Appointed Lucy To as Chief Financial Officer Announced founding of a new Clinical Advisory Board MIAMI, Aug. 08, 2024 (GLOBE NEWSWIRE) -- SAB BIO (Nasdaq: SABS)... ► Artikel lesen | |
| 05.08.24 | SAB Biotherapeutics, Inc.: SAB BIO Announces Founding of Clinical Advisory Board to Guide the Development of SAB-142 for Type 1 Diabetes | 530 | GlobeNewswire (Europe) | MIAMI, Aug. 05, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing... ► Artikel lesen | |
| 31.07.24 | SAB Biotherapeutics, Inc.: SAB BIO Appoints Lucy To as Chief Financial Officer | 157 | GlobeNewswire (Europe) | MIAMI, July 31, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is... ► Artikel lesen | |
| 20.06.24 | SAB Biotherapeutics, Inc.: SAb Biotherapeutics Rebrands as SAB BIO | 182 | GlobeNewswire (Europe) | New name, logo and website updates, stock symbol will remain SABS With new brand identity, SAB BIO continues drive towards serious unmet needs in type 1 diabetes MIAMI, June 20, 2024 (GLOBE NEWSWIRE)... ► Artikel lesen | |
| 30.05.24 | SAB Biotherapeutics, Inc.: SAB Biotherapeutics Announces Departure of Chief Financial Officer | 248 | GlobeNewswire (Europe) | MIAMI, May 30, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the "Company" or "SAB"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform developing a human... ► Artikel lesen | |
| 21.05.24 | SAB Biotherapeutics, Inc.: FDA Provides Clearance to IND Application for Type 1 Diabetes Therapy SAB-142 by SAB Biotherapeutics | 283 | GlobeNewswire (Europe) | MIAMI, May 21, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics (Nasdaq: SABS) (the "Company" or "SAB"), today announced that the U.S. Food and Drug Administration (FDA) has provided clearance for the... ► Artikel lesen | |
| 20.05.24 | SAB Biotherapeutics, Inc.: SAB Biotherapeutics Announces Q1 2024 Financial Results and Provides Company Updates | 298 | GlobeNewswire (Europe) | MIAMI, May 20, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing... ► Artikel lesen | |
| 16.04.24 | SAB Biotherapeutics, Inc.: SAB Biotherapeutics Provides SAB-142 Trial Update | 160 | GlobeNewswire (Europe) | MIAMI BEACH, Fla., April 16, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: SABS), ("SAB" or the "Company"), a clinical-stage biopharmaceutical company with a novel immunotherapy platform... ► Artikel lesen | |
| 29.03.24 | SAB Biotherapeutics, Inc.: SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results | 972 | GlobeNewswire (Europe) | Sioux Falls, SD, March 29, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics Reports Full Year 2023 Operating and Financial Results March 29, 2024 SAB-142 Phase 1 trial on track for data release during... ► Artikel lesen |
19 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,00 | -1,10 % | BioNTech: Die charttechnische Lage bleibt angespannt | Das Mainzer Biotechnologieunternehmen schien 2024 eine ersehnte Trendwende einzuleiten. Die 200-Tage-Linie wurde zurückerobert, und die Kurse hielten sich bis Ende Februar darüber. Doch dann folgte... ► Artikel lesen | |
| CUREVAC | 2,718 | +0,30 % | CureVac Aktie: Bemerkenswerter Aufschwung! | Der Tübinger Impfstoffhersteller meldet beeindruckendes Quartalsergebnis mit 542,57 Millionen USD Umsatz, während die Aktie zwischen 2,06 und 4,98 EUR schwankt. Die CureVac-Aktie zeigte am Donnerstag... ► Artikel lesen | |
| AMGEN | 286,00 | +0,49 % | Amgen-Aktie setzt Aufwärtstrend fort - Wann kommt die nächste Korrektur? | Anzeige / WerbungDie Amgen-Aktie (ISIN: US0311621009) bleibt in einem starken Aufwärtstrend und legt gestern 0,47 % auf 318,65 USD zu. Seit dem Dezember-Tief bei rund 240 USD konnte die Aktie um mehr... ► Artikel lesen | |
| NOVAVAX | 7,000 | -0,16 % | Novavax Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| BIOGEN | 129,85 | -0,57 % | Biogen Plans For State-of-the-Art Global Headquarters At Kendall Common, Set To Open In 2028 | WESTON (dpa-AFX) - Biogen Inc. (BIIB) announced Monday plans for its new global headquarters at Kendall Common, located at 75 Broadway in Cambridge, as part of a multi-year real estate consolidation... ► Artikel lesen | |
| MAINZ BIOMED | 5,695 | -100,00 % | Mainz Biomed Aktie: Platzt am Montag die Bombe? Diese Neuigkeiten müssen Anleger dringend beachten! | ||
| VIKING THERAPEUTICS | 25,000 | -4,65 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 2 VENTURE-Oral Dosing Trial of VK2735 Tablet Formulation in Patients with Obesity | 13-Week Study Evaluating the Safety and Efficacy of Oral VK2735 Dosed Once Daily
Results Expected in 2H25
SAN DIEGO, March 26, 2025 /PRNewswire/ -- Viking Therapeutics... ► Artikel lesen | |
| INTELLIA THERAPEUTICS | 7,960 | -1,99 % | Intellia Therapeutics, Inc.: Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with ... | CAMBRIDGE, Mass., March 26, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based... ► Artikel lesen | |
| BIOCRYST PHARMACEUTICALS | 7,518 | +0,32 % | BioCryst Pharmaceuticals, Inc.: BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | RESEARCH TRIANGLE PARK, N.C., March 06, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst's board of directors granted... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 0,950 | -3,75 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics to Present at TD Cowen 45th Annual Health Care Conference | Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,226 | -0,13 % | Assessing Pacific Biosciences: Insights From 6 Financial Analysts | ||
| SAREPTA THERAPEUTICS | 65,98 | -3,59 % | Sarepta-Aktie crasht: Todesfall überschattet Investmentstory | Mit einem Minus von gut 27 Prozent gehörte die Aktie der amerikanischen Biotech-Gesellschaft Sarepta Therapeutics am Dienstag zu den größten Verlierern an der Technologie-Börse Nasdaq. Auslöser war... ► Artikel lesen | |
| EXELIXIS | 34,160 | -2,23 % | Exelixis gets FDA nod for its advanced neuroendocrine tumor treatment | ||
| VAXART | 0,462 | +3,77 % | Vaxart, Inc.: Vaxart Provides Business Update and Reports Full Year 2024 Financial Results | Initiated Phase 1 clinical trial evaluating its second-generation oral norovirus vaccine constructs with topline data expected as early as mid-2025 Continues per protocol follow-up for the COVID-19... ► Artikel lesen | |
| TEMPUS AI | 56,30 | -2,71 % | Tempus AI Aktie: Anstehende Entwicklungen im Check | Die Tempus AI Aktie steht aktuell im Fokus der Anleger, nachdem mehrere Direktoren des Unternehmens in erheblichem Umfang Anteile veräußert haben. Am 17. März 2025 haben drei Vorstandsmitglieder Aktien... ► Artikel lesen |
SAB BIOTHERAPEUTICS INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,690 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SAB BIOTHERAPEUTICS INC finden Sie auf Wallstreet Online.
